2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.
Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.
According to Janni, the APHINITY trial, is one of the trials that many are still excited about regarding treatments for HER2-positive breast cancer.
In terms of new agents, Janni states that it will be interesting to see data on other targeted agents such as CDK4/6 inhibitors in the HER2-positive setting. There is interesting data suggesting that this could be beneficial to patients.
Related Content: